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Purpose: To evaluate the efficacy of triamcinolone as an aid in vitreous
visualization during 3D-vitrectomy for the treatment of diabetic vitreo-
macular traction. Methods: Prospective interventional study in patients
with symptomatic vitreomacular traction. Pre- and postoperative assess-
ments included visual acuity, retinography, intraocular pressure and
optical coherence tomography. All patients were operated by the same
surgeon (OOMJ). Triamcinolone was used as a visual enhancer during
surgery. The parameters of the vitreophage (Accurus 800CS, Alcon) were
set to the 3D- system (dual dynamic drive), contact lenses (plain and wide
angle) being used for visualization. Peripheral 360º vitreous circumcision
at high cut rate was performed, carefully releasing the vitreomacular
adhesion at the posterior pole by means of an appropriate pic or vitreore-
tinal forceps. Results: The sample consisted of five consecutive patients
(five eyes), three female and two male, with symptomatic vitreomacular
traction. Their age ranged from 54 to 71 years (mean 62.6 ± 6.3 years).
During the surgical procedure, the areas with vitreomacular traction were
properly visualized and identified after the application of triamcinolone.
No complications were recorded during or after surgery. There was a
statistically significant improvement in visual acuity after the surgical
procedure (p=0.0313). Conclusion: Triamcinolone facilitates the surgical
treatment of vitreomacular traction by improving visibility of both the
vitreous humor and the vitreous-retina interface. Triamcinolone-assisted
3D vitrectomy proved to be an effective procedure in these cases.
ABSTRACT
INTRODUCTION
The incomplete detachment of the posterior vitreous may affect the
vitreous-retina interface and induce structural and functional changes of
the retina secondary to the centripetal traction force exerted by the vi-
treous(1-2). The macular region may become distorted and a minor traction
detachment of the retina may occur(2-3). Even though the separation of the
posterior vitreous from the retina, in the area of abnormal adhesion, may
occur spontaneously(4-5), vitrectomy should be considered in cases of sym-
ptomatic vitreomacular traction with reduced visual acuity or metamorpho-
psia(6-7). Optical coherence tomography (OCT) shows the vitreous-retinal
interface in detail, and may reveal structural alterations of the retina
resulting from vitreomacular traction, thus helping in the diagnosis choo-
sing an appropriate approach(8).
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Despite advances in surgical instrumentation and techni-
ques, the vitrectomy procedure continues to demand both skill
and experience. The removal of the vitreous is a particularly
challenging procedure, partly because of its transparency(9). To
assist in the visualization of the vitreous during vitrectomy,
intraoperative triamcinolone acetonide was used. The triam-
cinolone acetonide-assisted pars plana vitrectomy technique
has been previously described(10-11), although not in vitreoma-
cular traction; we consider its use in this indication as a useful
tool for the success of the surgery and to decrease iatrogenic
risks. The objective of this study is to evaluate the effective-
ness of triamcinolone as an aid in vitreous visualization during
vitrectomy for diabetic vitreomacular traction.
METHODS
Interventional case series of patients with symptomatic
vitreomacular traction from the Department of Ophthalmolo-
gy, University of São Paulo Medical School General Hospital,
were submitted to a 20- or 25-gauge vitrectomy and prospec-
tively evaluated for a minimum period of 3 months. Exclusion
criteria were: cataract, corneal opacity, glaucoma, vitreous
hemorrhage and loss of follow-up.
Pre- and postoperative assessments included visual acui-
ty (Snellen), retinography, Goldmann applanation tonometry
and OCT. The images obtained with the Stratus OCT version
4.0 (Carl Zeiss Meditec) were taken at the macular thickness
program with the cursor placed manually in the center of the
fovea, whenever the foveal depression was visible.
All patients were submitted to vitrectomy performed by the
same surgeon (OOMJ), between January and July 2006. During
surgery, prior core vitrectomy was performed, and triamci-
nolone (Kenalog®, Bristol-Myers Squibb Company) was then
injected through a soft cannula, in a sufficient amount to stain
the vitreous humor. The parameters of the vitreophage (Ac-
curus 800CS, Alcon) were set to the 3D system (dual dynamic
drive), and contact lenses (plain and wide angle) were used for
Figure 1 - Preoperative: patient 1, 54-year-old, female, with diabetic retinopathy previously treated with panphotocoagulation by argon laser, with
vitreomacular traction. Retinography of the left eye shows laser scars and a lamellar hole (A). Stratus OCT evidenced a lamellar hole with
vitreomacular traction on the edge (yellow arrow) (B), incomplete vitreous detachment around the optic nerve (white arrow) (C) and an area of
 subretinal hyporeflectivity (red arrow) indicating a shallow tractional retinal detachment (D).
A B
C D
Table 1. Characteristics of patients with diabetic vitreomacular traction submitted to triamcinolone-guided 3D vitrectomy at the University
of São Paulo Medical School General Hospital, São Paulo, Brazil - 2006
Patients Age* Sex Panphotocoagulation Preoperative VA Vitrectomy Follow-up Postoperative VA
1 54 Female 18 20/60 20-Gauge 9 20/20
2 63 Male 24 20/100 25-Gauge 6 20/25
3 65 Female  - 20/80 20-Gauge 3 20/30
4 71 Female 14 20/200 25-Gauge 3 20/30
5 60 Male 18 20/100 25-Gauge 6 20/30
*
= age in years;  = time from last laser therapy session (in months);  = visual acuity according to the Snellen table;  = follow-up period (in months)
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visualization. Initially, a 360° vitreous circumcision at high cut
rate was performed to avoid increasing macular traction by the
adherent vitreous. After this initial approach, the vitreomacular
adhesion was carefully released with a pic. Tighter adhesions
were then removed with an appropriate vitreoretinal forceps.
Upon removal of the vitreomacular tractions, a detailed inspec-
tion of both the posterior pole and the periphery was performed,
in order to detect preexisting or iatrogenic ruptures. Air-gas ex-
change was performed as required.
Each variable was analyzed through descriptive statistics.
For quantitative variables, this analysis included minimum and
maximum values, mean and standard deviation. For qualitative
variables, absolute and relative frequencies were calculated.
The visual acuity measurement was converted to logMAR and
analyzed through a non-parametric sign test. The level of signi-
ficance used for the test was 5%. The study was approved by
the Institutional Review Board/ Research Ethics Committee of
the University of São Paulo Medical School General Hospital
and all the patients signed an Informed Consent Form.
RESULTS
The sample consisted of five consecutive patients (five eyes)
with symptomatic vitreomacular traction. Three patients (60%)
were female and two (40%), male. The age ranged from 54 to 71
years (mean 62.6 ± 6.3 years). All patients had type 2 diabetes
mellitus, and 80% had diabetic retinopathy and had under-
gone panphotocoagulation with argon laser at least one year
ago (Table 1).
Preoperative visual acuity ranged from 20/200 to 20/60
(logMAR, 1.00 to 0.50 - mean 0.70 ± 0.18). On OCT, all patients
presented hyperreflective structures, marginal to the optical
nerve and in the macular region, both sites corresponding to
areas of vitreomacular traction.
A B
C D
Figure 2 - Intraoperative. Triamcinolone-guided 3D-vitrectomy for diabetic vitreomacular traction (A). 360° vitreous circumcision at high cut rate (B).
 Vitreomacular adhesion carefully released with a pic (C). Removal of remaining vitreous after tractions were released (D).
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Figure 3 - Postoperative: patient showing visual acuity improvement 9 months after the surgical procedure. Stratus OCT evidenced macular
 structure recovery. Normal foveal thickness (185µm).
Two patients underwent a 20-gauge vitrectomy and three,
25-gauge. During the surgical procedure, the areas with vi-
treomacular traction were properly visualized and identified
after the application of triamcinolone. Air-gas exchange
was not required in any of the patients. No complications
were observed during or after surgery. Intraocular pressure
increase was not detected throughout the follow-up period.
There was a significant improvement in visual acuity
(p=0.0313) with measurements ranging, on the last follow-up
visit, from 20/30 to 20/20 (logMAR 0.20 to 0.00 - mean 0.14 ±
0.09). The follow-up period ranged from 3 to 9 months (mean
5.4 ± 2.5 months). One case was selected to illustrate the sur-
gical procedure and the outcome (Figures 1, 2 and 3).
DISCUSSION
Triamcinolone acetonide-assisted visualization of the vi-
treous has been reported as a helpful tool for surgeons perfor-
ming procedures such as internal limiting membrane peeling or
posterior vitreous separation(9-16). However, this is the first
study to describe the use of triamcinolone-guided 3D vitrecto-
my in the treatment of diabetic vitreomacular traction.
Anomalous posterior vitreous detachment results when
the extent of vitreous liquefaction exceeds the degree of wea-
kening of vitreoretinal adherence and traction is exerted at this
interface. There are various causes for this imbalance between
the degree of gel liquefaction and weakening of vitreoretinal
adhesion(17). Systemic conditions, such as diabetes, induce
biochemical and structural alterations in the vitreous(18). In
this study, all patients had diabetes mellitus and most of them
had been previously treated with panphotocoagulation with
argon laser. In addition to the underlying systemic disease,
laser therapy may have played some role in the etiology of
vitreomacular traction in these patients.
During vitrectomy for vitreomacular traction, the traction
may increase in the areas with established vitreoretinal adhe-
sion, worsening the visual prognosis. However, no intraope-
rative complications were observed during triamcinolone-gui-
ded 3D vitrectomy. The 3D technology provides flow control
of the removed vitreous, adjusted both to the cutting speed
and to the vacuum produced by a customized treadle. In addi-
tion, triamcinolone acted as a facilitator of the surgical pro-
cedure, by improving visibility of both the vitreous humor and
the vitreous-retina interface. Therefore, triamcinolone-guided
3D vitrectomy proved effective in these cases. These findings
warrant further studies to evaluate the long-term effects on
retinal structure and retinal function.
RESUMO
Objetivo: Avaliar a eficácia da triancinolona como marcador
vítreo na vitrectomia 3D para tratamento da tração vitreoma-
cular do diabetes. Métodos: Realizou-se um estudo prospec-
tivo intervencionista numa série de portadores de tração vi-
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treomacular sintomática. Na avaliação pré e pós-operatória
foram realizadas a medida da acuidade visual, retinografia,
pressão intra-ocular e tomografia de coerência óptica. Todos
pacientes foram submetidos à vitrectomia pelo mesmo cirur-
gião (OOMJ). No intra-operatório, utilizou-se triancinolona
como marcador vítreo. Os parâmetros do vitreófago (Accurus
800CS, Alcon) foram programados no sistema 3D (dual dyna-
mic drive), sendo utilizadas lentes de contato (grande angular
e plana) para visibilização. Realizou-se circuncisão vítrea pe-
riférica 360° com alto corte, desfazendo cuidadosamente as ade-
sões vitreomaculares no pólo posterior por meio de gancho ou
pinças vítreo-retinianas adequadas. Resultados: A amostra
foi composta por cinco pacientes (cinco olhos) consecutivos
com tração vitreomacular sintomática. Três eram do sexo fe-
minino e dois, do masculino. A idade variou de 54 a 71 anos
(média de 62,6 ± 6,3 anos). Durante o procedimento cirúrgico,
os locais de tração vitreomacular foram identificados com boa
visibilidade após aplicação da triancinolona. Não foram obser-
vadas intercorrências tanto no intra quanto no pós-operatório.
Houve melhora estatisticamente significante na acuidade vi-
sual após procedimento cirúrgico (p=0,0313). Conclusão: A
triancinolona tem ação facilitadora no tratamento cirúrgico da
tração vitreomacular, por melhorar visibilização tanto do hu-
mor vítreo quanto da interface vítreo-retina. A cirurgia de
vitrectomia 3D, guiada por triancinolona, mostrou-se ser um
procedimento eficiente nesses casos.
Descritores: Corpo vítreo/cirurgia; Vitrectomia/métodos; Ma-
cula lútea; Triancinolona; Complicações pós-operatórias; To-
mografia de coerência óptica; Acuidade visual
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